Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env-V2

The RV144 trial demonstrated 31% vaccine efficacy (VE) at preventing HIV-1 infection(1). Antibodies against the HIV-1 envelope variable loops 1 and 2 (V1/V2) domain correlated inversely with infection risk(2). We hypothesized that vaccine-induced immune responses against V1/V2 would selectively impa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Rolland, Morgane, Edlefsen, Paul T., Larsen, Brendan B., Tovanabutra, Sodsai, Sanders-Buell, Eric, Hertz, Tomer, deCamp, Allan C., Carrico, Chris, Menis, Sergey, Magaret, Craig A., Ahmed, Hasan, Juraska, Michal, Chen, Lennie, Konopa, Philip, Nariya, Snehal, Stoddard, Julia N., Wong, Kim, Zhao, Hong, Deng, Wenjie, Maust, Brandon S., Bose, Meera, Howell, Shana, Bates, Adam, Lazzaro, Michelle, O'Sullivan, Annemarie, Lei, Esther, Bradfield, Andrea, Ibitamuno, Grace, Assawadarachai, Vatcharain, O'Connell, Robert J., deSouza, Mark S., Nitayaphan, Sorachai, Rerks-Ngarm, Supachai, Robb, Merlin L., McLellan, Jason S., Georgiev, Ivelin, Kwong, Peter D., Carlson, Jonathan M., Michael, Nelson L., Schief, William R., Gilbert, Peter B., Mullins, James I., Kim, Jerome H.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2012
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3551291/
https://ncbi.nlm.nih.gov/pubmed/22960785
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature11519
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge